The efficacy of blocking antibodies against NGF (e.g., tanezumab, fasinumab) in patients with pain or cancer-induced pain have been investigated in some clinical trials (NCT00830180) (Mizumura and Murase, 2015). This evidence concerns the gene NGF and cancer.